Four new drugs get positive EMEA opinions
The European Medicines Agency is recommending that four new drugs be allowed onto the market in Europe including a new therapy from Sanofi-Aventis for the treatment of atrial fibrillation.
News
Novartis and GSK vaccines for swine flu get go ahead from EMEA
The European Medicines Agency has recommended that two vaccines for influenza A (H1N1), known as swine flu, be granted a European Union-wide marketing authorisation. The vaccines are Focetria from Novartis and Pandemrix from GlaxoSmithKline.
NicOx files NDA for a new chemical entity to treat osteoarthritis
NicOx SA said it has filed a new drug application (NDA) with the US Food and Drug Administration for naproxcinod for the treatment of osteoarthritic pain.
Pharma business model must change, says sanofi-aventis executive
The pharmaceutical industry must move quickly to change its business model in order to be able to deliver new products in the future, Jean-Claude Muller of sanofi-aventis told a meeting of industry executives.
Qiagen acquires DxS as a push into personalised medicine
Qiagen NV, a Dutch provider of sample and assay technologies, has acquired DxS Ltd, of Britain in a transaction that will expand Qiagen’s market position in molecular diagnostics for personalised medicine.
Brussels seeks proposals for €156.3 million of research projects
The European Commission’s research partnership with industry aimed at finding new ways of making drug development more efficient is preparing to launch a new series of projects valued at €156.3 million
Cell Medica receives £1.95 million to commercialise cell therapy
Cell Medica Ltd, an early-stage cellular therapeutics company, has received £1.95 million in new funding in order to commercialise its lead product, a cell therapy technique which protects patients from infection following a bone marrow transplant.
AstraZeneca to pay $125 million upfront for two drug development programmes
AstraZeneca Plc is to pay $125 million upfront for two drug development programmes that address opioid-induced constipation. The payments are part of its exclusive licensing agreement with the US-based Nektar Therapeutics.
Risk factors for prostate cancer identified
An international team of scientists has reported finding four new single-letter variations in the sequence of the human genome which confers an increased risk of prostate cancer. The findings were published online in Nature Genetics.
Wellcome Trust and Merck & Co create a social business for vaccines
The Wellcome Trust and Merck & Co have created a social business to develop affordable vaccines for diseases prevalent in low-income countries.